Please ensure Javascript is enabled for purposes of website accessibility

Why Acadia Pharmaceuticals Is Plummeting

By Brian Feroldi - Nov 27, 2018 at 3:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares take a dive after management announces a fresh capital raise. Here's what investors need to know.

What happened

After management announced its intention to raise capital through a common stock offering, shares of Acadia Pharmaceuticals (ACAD 1.99%), a commercial-stage biopharma focused on diseases of the central nervous system, fell 12% as of 3:07 p.m. EST on Tuesday.

So what 

Acadia announced its intention to raise up to $230 million through a secondary offering.

That news isn't sitting well with investors because the company's share price has been falling all year. Acadia started 2018 with its share price trading for more than $30. The stock closed yesterday's trading session at less than $20. The declining share price means that investors are going to have to endure more dilution than they would have if management had chosen to raise capital earlier in the year. 

Businessman setting fire to money.

Image source: Getty Images.

On the plus side, Acadia's stock has rebounded from its 52-week lows after some favorable commentary was released by the FDA, so the timing of this capital raise could have been worse.

Now what

Earlier in November, Acadia told investors that it planned on ending the year with at least $160 million in cash on its books, so the company isn't in dire need of a cash injection just yet. However, given that the company's net loss in 2018 is probably going to be more than $230 million, it is understandable why management wants to act now. 

For investors, the commentary from the FDA should help the company to recover from a debacle that surfaced earlier this year after a CNN report highlighted hundreds of patient deaths that could have been related to the use of Nuplazid. Now the company can remain squarely focused on what's important: ramping up sales of Nuplazid as quickly as possible and working to expand the drug's labeling. If it can execute on those two fronts, the share price will take care of itself.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acadia Pharmaceuticals Stock Quote
Acadia Pharmaceuticals
$14.37 (1.99%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.